<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04694404</url>
  </required_header>
  <id_info>
    <org_study_id>CH-PI-105</org_study_id>
    <nct_id>NCT04694404</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of S-1 Plus Oxaliplatin in First-line Treatment of Ederly Patients With Advanced Gastric Cancer</brief_title>
  <official_title>The Efficacy and Safety of S-1 Plus Oxaliplatin in First-line Treatment of Ederly Patients With Advanced or Recurrent Gastric Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aiping Zhou</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese Academy of Medical Sciences</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Elderly patients have poor tolerance and physical condition, we will prove 2-week schedule of&#xD;
      oxaliplatin plus S-1 have a good efficacy and a better safety for elderly patients with&#xD;
      advanced or recurrent gastric cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      3-week plan of S-1 plus Oxaliplatin has been widely used,but it also has cumulative&#xD;
      toxicity.Meanwhile elderly patients have poor tolerance and physical condition, we will prove&#xD;
      2-weeks schedule of oxaliplatin plus S-1 have a good efficacy and a better safety for elderly&#xD;
      patients with advanced or recurrent gastric cancer.Untreated elderly patients with advanced&#xD;
      or recurrent gastric cancer will receive Oxaliplatin 85 mg/m2 (D1, q2w) and S-1(40mg BID for&#xD;
      body surface area &lt; 1.25 m2; 50mg BID for body surface area of 1.25-1.5m2; and 60mg BID for&#xD;
      body surface area &gt;1.5 m2; D1-10, q2w) as the first-line treatment. We will investigate the&#xD;
      efficacy and safety of the combination treatment, and expect to provide a good effective&#xD;
      treatment plan and a better safety for elderly patients with advanced or recurrent gastric&#xD;
      cancer in China.The primary endpoint is progression-free survival(PFS), and the secondary&#xD;
      endpoints are objective response rate(ORR), overall survival(OS) and the safety.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 11, 2016</start_date>
  <completion_date type="Anticipated">December 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Single Group Assignment Eledrly Patients with Untreated Advanced or Recurrent Gastric Cancer</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PFS</measure>
    <time_frame>6 months</time_frame>
    <description>Progression-free survival</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ORR</measure>
    <time_frame>6 months</time_frame>
    <description>Objective response rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>1 year</time_frame>
    <description>Overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of participants with treatment-related adverse events as assessed by CTCAE v4.0</measure>
    <time_frame>1 year</time_frame>
    <description>Safety</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>S-1 Plus Oxaliplatin</condition>
  <arm_group>
    <arm_group_label>S-1 Plus Oxaliplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oxaliplatin 85 mg/m2 (D1, q2w) and S-1 (40mg BID for body surface area &lt; 1.25 m2; 50mg BID for body surface area of 1.25-1.5 m2; and 60mg BID for body surface area &gt;1.5 m2; D1-10, q2w)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S-1,Oxaliplatin</intervention_name>
    <description>Oxaliplatin 85 mg/m2 (D1, q2w) and S-1 (40mg BID for body surface area &lt; 1.25 m2; 50mg BID for body surface area of 1.25-1.5 m2; and 60mg BID for body surface area &gt;1.5 m2; D1-10, q2w)</description>
    <arm_group_label>S-1 Plus Oxaliplatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed unresectable or recurrent gastric or gastroesophageal&#xD;
             junction adenocarcinoma;&#xD;
&#xD;
          -  Aged≥60&#xD;
&#xD;
          -  ability of oral administration;&#xD;
&#xD;
          -  CT or MRI can be used to assess measurable or non-measurable lesions according to the&#xD;
             criteria of Response Evaluation Criteria In Solid Tumours (RECIST 1.1);&#xD;
&#xD;
          -  Untreated&#xD;
&#xD;
          -  more than 12 months after the last adjuvant/neoadjuvant chemotherapy;&#xD;
&#xD;
          -  ECOG=0-2;&#xD;
&#xD;
          -  Available organ function: ALT≤2.5xULN;AST≤2.5xULN;If patients have&#xD;
             hepaticmetastasis,ALT≤2.5xULN,AST≤2.5xULN;ALP≤2xULN;TBIL≤1.0xULN;NEUT≥1.5×109/L;PLT≥10&#xD;
             0×109/L;Hb≥90g/L;Creatinine≤1.0xULN;Creatinine Clearance≥60ml/min&#xD;
&#xD;
          -  Informed consent;&#xD;
&#xD;
          -  Expected survival more than 3 months;More than 3 weeks after major surgery.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Neoadjuvant and/or adjuvant have been treated with more than two plans;&#xD;
&#xD;
          -  In the past two years, the total dose of oxaliplatin≥800mg/m2;&#xD;
&#xD;
          -  Other cancers in the past 5 years,except for cervical carcinoma in situ or&#xD;
             non-melanoma skin cancer;&#xD;
&#xD;
          -  Symptomatic brain metastases or soft meningeal metastasis;&#xD;
&#xD;
          -  Myocardial infarction (in the last 6 months), severe instability angina, congestive&#xD;
             heart failure;&#xD;
&#xD;
          -  Serious complications (including intestinal paralysis, gastrointestinal obstruction,&#xD;
             interstitial pneumonia, pulmonary fibrosis, uncontrolled diabetes, renal insufficiency&#xD;
             and cirrhosis); Chronic nausea, vomiting or diarrhea (more than 4 times per day, or&#xD;
             watery);Gastrointestinal bleeding requires regular blood transfusion;HIV or AIDS;&#xD;
             Mental illness; Neuropathy grade≥2;Infectious diseases or inflammation,&#xD;
             temperature≥38℃;&#xD;
&#xD;
          -  Known allergy to drugs in the study;&#xD;
&#xD;
          -  Pregnant or lactating women;&#xD;
&#xD;
          -  Both male and female subjects of potential fertility have to agree effective birth&#xD;
             control during the entire study;&#xD;
&#xD;
          -  Experimental drugs used no more than 4 weeks;&#xD;
&#xD;
          -  Other conditions the researchers considered ineligible for the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aiping Zhou, Doctor</last_name>
    <role>Study Director</role>
    <affiliation>National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Aiping Zhou, Doctor</last_name>
    <phone>+86 13691161998</phone>
    <email>zhouap1825@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Cancer Center/Cancer Hospital, Chinese ACademy of Medical Sciences and Peking Union Medical College</name>
      <address>
        <city>Beijing</city>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aiping Zhou, Doctor</last_name>
      <phone>+86 13691161998</phone>
      <email>zhouap1825@126.com</email>
    </contact>
    <investigator>
      <last_name>Aiping Zhou, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>November 5, 2017</study_first_submitted>
  <study_first_submitted_qc>January 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 5, 2021</study_first_posted>
  <last_update_submitted>January 4, 2021</last_update_submitted>
  <last_update_submitted_qc>January 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Chinese Academy of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Aiping Zhou</investigator_full_name>
    <investigator_title>Chief physician</investigator_title>
  </responsible_party>
  <keyword>S-1,Oxaliplatin,Advanced or Recurrent Gastric Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

